Rituximab biosimilar - Pfizer

Drug Profile

Rituximab biosimilar - Pfizer

Alternative Names: PF-05280586; PF-5280586

Latest Information Update: 05 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Follicular lymphoma
  • Phase I/II Rheumatoid arthritis

Most Recent Events

  • 07 Oct 2016 Safety, pharmacokinetic and pharmacodynamic results from the phase I/II trial in Rheumatoid arthritis were presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Mar 2016 Pfizer completes the extension REFLECTIONS B328-04 trial for Rheumatoid arthritis in USA, Australia, Canada, Colombia, Germany, Israel, Mexico, Russia, Spain, South Africa and the UK (NCT01643928)
  • 14 Sep 2015 Phase-III clinical trials in Follicular lymphoma (First-line therapy, In the elderly, In adults) in Belarus, Croatia, France, Italy, Japan, Poland, Russia, South Africa, South Korea, Switzerland, Thailand, Turkey, Ukraine and United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top